ClinicalTrials.Veeva

Menu

Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Hepatitis C

Treatments

Other: Triple therapy

Study type

Observational

Funder types

Other

Identifiers

NCT02877199
69HCL16_0552

Details and patient eligibility

About

The hypothesis was to check whether baseline anti-E1E2 antibodies were correlated with the on-treatment viral kinetics and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving protease inhibitor-based triple therapy.

Enrollment

19 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HCV patients with compensated cirrhosis (Child-Pugh A)
  • HCV genotype 1
  • non-responders to a previous course of interferon (IFN)/ribavirin
  • receiving boceprevir or telaprevir

Exclusion criteria

Trial design

19 participants in 1 patient group

HCV triple therapy
Description:
Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy
Treatment:
Other: Triple therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems